Jump to content
RemedySpot.com

Targeting Hepatitis B virus infected cells with a T-cell receptor like antibody.

Rate this topic


Recommended Posts

Posted

J Virol. 2010 Dec 15. [Epub ahead of print]

Targeting Hepatitis B virus infected cells with a T-cell receptor like antibody.

Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javaid A, Pollicino T, Li L,

Kennedy PT, Lopatin U, Macary PA, Bertoletti A.

Viral Hepatitis Laboratory, Infection & Immunity Program, Singapore Institute

for Clinical Sciences, A*STAR, Singapore; Immunology Program and Department of

Microbiology, National University of Singapore, Singapore; Institute of Cell and

Molecular Science, Barts and The London School of Medicine, London, UK; Unit of

Clinical and Molecular Hepatology, University Hospital of Messina, Messina,

Italy; Roche Pharma research and Early development: Translational Medicine

-Virology, Palo Alto, USA; Emerging Viral Diseases, Duke-NUS Graduate Medical

School, Singapore; Yong Loo Lin School of Medicine, National University of

Singapore, Singapore.

Abstract

Virus-specific CD8 T cells are activated when their T cell receptors (TCR)

recognize the specific viral-peptide MHC-class I complexes (pMHC) present on the

surface of infected cells. Antibodies able to recognize the specific pMHC can

mimic TCR specificity and represent both a valuable biological tool to visualize

pMHC complexes on infected cells and serve as a delivery system for highly

targeted therapies. To evaluate these possibilities we created a monoclonal

antibody able to specifically recognize a hepatitis B virus (HBV) envelope

epitope (Env 183-91) presented by HLA-A201 molecule and we tested its ability to

recognize HBV infected hepatocytes and to deliver a cargo to specific target. We

demonstrate that this antibody detects and visualizes the processed product of

HBV proteins produced in naturally HBV infected cells, is not inhibited by

soluble HBV proteins present in patients sera and mediates intracellular

delivery of a fluorescent molecule to target cells. Additionally, when compared

to CD8 T cells specific for the same HBV epitope, the TCR-like antibody has both

a superior sensitivity and a specificity focused on distinct amino acid within

the epitope. These data demonstrate that a T cell receptor-like antibody can be

used to determine the quantitative relation between HBV replication and specific

Ag presentation to CD8 T cells and serve as a novel therapeutic delivery

platform for personalized health care of HBV infected patients.

PMID: 21159876 [PubMed - as supplied by publisher]

Posted

J Virol. 2010 Dec 15. [Epub ahead of print]

Targeting Hepatitis B virus infected cells with a T-cell receptor like antibody.

Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javaid A, Pollicino T, Li L,

Kennedy PT, Lopatin U, Macary PA, Bertoletti A.

Viral Hepatitis Laboratory, Infection & Immunity Program, Singapore Institute

for Clinical Sciences, A*STAR, Singapore; Immunology Program and Department of

Microbiology, National University of Singapore, Singapore; Institute of Cell and

Molecular Science, Barts and The London School of Medicine, London, UK; Unit of

Clinical and Molecular Hepatology, University Hospital of Messina, Messina,

Italy; Roche Pharma research and Early development: Translational Medicine

-Virology, Palo Alto, USA; Emerging Viral Diseases, Duke-NUS Graduate Medical

School, Singapore; Yong Loo Lin School of Medicine, National University of

Singapore, Singapore.

Abstract

Virus-specific CD8 T cells are activated when their T cell receptors (TCR)

recognize the specific viral-peptide MHC-class I complexes (pMHC) present on the

surface of infected cells. Antibodies able to recognize the specific pMHC can

mimic TCR specificity and represent both a valuable biological tool to visualize

pMHC complexes on infected cells and serve as a delivery system for highly

targeted therapies. To evaluate these possibilities we created a monoclonal

antibody able to specifically recognize a hepatitis B virus (HBV) envelope

epitope (Env 183-91) presented by HLA-A201 molecule and we tested its ability to

recognize HBV infected hepatocytes and to deliver a cargo to specific target. We

demonstrate that this antibody detects and visualizes the processed product of

HBV proteins produced in naturally HBV infected cells, is not inhibited by

soluble HBV proteins present in patients sera and mediates intracellular

delivery of a fluorescent molecule to target cells. Additionally, when compared

to CD8 T cells specific for the same HBV epitope, the TCR-like antibody has both

a superior sensitivity and a specificity focused on distinct amino acid within

the epitope. These data demonstrate that a T cell receptor-like antibody can be

used to determine the quantitative relation between HBV replication and specific

Ag presentation to CD8 T cells and serve as a novel therapeutic delivery

platform for personalized health care of HBV infected patients.

PMID: 21159876 [PubMed - as supplied by publisher]

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...